DRNA - Dicerna Pharmaceuticals - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

with an average price target of $2.61. This is a potential upside of $2.61 (0%) from yesterday's end of day stock price of $0.

Dicerna Pharmaceuticals's activity chart (see below) currently has 91 price targets and 57 ratings on display.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 75.96% with an average time for these price targets to be met of 309.55 days.

Most recent stock forecast was given by KEAY NAKAE from CHARDAN CAPITAL on 08-Dec-2021. First documented stock forecast 13-Mar-2015.

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$28

$-10.22 (-26.74%)

3 years 1 months 22 days ago
(08-Dec-2021)

1/2 (50%)

$-10 (-26.32%)

101

Buy

$30

$-8.22 (-21.51%)

$30

3 years 2 months 11 days ago
(19-Nov-2021)

2/3 (66.67%)

$-7.92 (-20.89%)

250

Hold

$35

$-3.22 (-8.42%)

$35

3 years 2 months 12 days ago
(18-Nov-2021)

3/6 (50%)

$-3.03 (-7.97%)

168

Hold

$38

$-0.22 (-0.58%)

$42

3 years 2 months 12 days ago
(18-Nov-2021)

8/10 (80%)

$-0.03 (-0.08%)

260

Hold

$25

$-13.22 (-34.59%)

3 years 5 months 19 days ago
(11-Aug-2021)

5/9 (55.56%)

$3.71 (17.43%)

195

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is DRNA (Dicerna Pharmaceuticals) average time for price targets to be met?

On average it took 309.55 days on average for the stock forecasts to be realized with a an average price target met ratio 75.96

Which analyst has the current highest performing score on DRNA (Dicerna Pharmaceuticals) with a proven track record?

MAYANK MAMTANI

Which analyst has the most public recommendations on DRNA (Dicerna Pharmaceuticals)?

Mayank Mamtani works at B. RILEY and has 24 price targets and 16 ratings on DRNA

Which analyst is the currently most bullish on DRNA (Dicerna Pharmaceuticals)?

Michael Schmidt with highest potential upside - $0

Which analyst is the currently most reserved on DRNA (Dicerna Pharmaceuticals)?

Edward Nash with lowest potential downside - -$18.22

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?